Compumedics Cash & Equivalents
The Cash & Short-Term Investments of Compumedics (CMP.AX) as of Oct 8, 2026 is 6.15 M AUD. In the previous year, Cash & Short-Term Investments was 2.69 M AUD — a change of 128.48% (higher).
Get this data via API
Financial Data API
Cash & Equivalents
6.15 MAUD
YoY
128.48%
Last updated:
The Compumedics Cash & Equivalents history
3 Years
10 Years
25 Years
Max
| YEAR | Cash & Equivalents | YoY |
|---|---|---|
| 6.15 MAUD | +128.48% | |
| 2.69 MAUD | +42.33% | |
| 1.89 MAUD | -50.22% | |
| 3.80 MAUD | -47.94% | |
| 7.29 MAUD | +7.74% | |
| 6.77 MAUD | +5.58% | |
| 6.41 MAUD | +39.42% | |
| 4.60 MAUD | +17.74% | |
| 3.91 MAUD | -4.78% | |
| 4.10 MAUD | +33.79% | |
| 3.07 MAUD | +37.49% | |
| 2.23 MAUD | +111.57% | |
| 1.05 MAUD | — |
Compumedics Stock analysis
Frequently Asked Questions about Compumedics stock
Cash & Short-Term Investments of Compumedics is 6.15 M AUD in 2026.
Cash & Short-Term Investments of Compumedics changed from 2.69 M AUD to 6.15 M AUD, representing a 128.48% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Cash & Short-Term Investments Compumedics since 2006 – with annual values, charts, and detailed analysis.
Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.
Cash & Short-Term Investments's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's Compumedics historically and in real time.
Balance Sheet — Compumedics
All Key Metrics — Compumedics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth